BRPI9607851B8 - combinação e formulação farmacêutica. - Google Patents
combinação e formulação farmacêutica. Download PDFInfo
- Publication number
- BRPI9607851B8 BRPI9607851B8 BRPI9607851A BRPI9607851A BRPI9607851B8 BR PI9607851 B8 BRPI9607851 B8 BR PI9607851B8 BR PI9607851 A BRPI9607851 A BR PI9607851A BR PI9607851 A BRPI9607851 A BR PI9607851A BR PI9607851 B8 BRPI9607851 B8 BR PI9607851B8
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- cis
- combination
- pharmaceutical formulation
- oxathiolan
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI9612992-1A BRPI9612992B1 (pt) | 1995-03-30 | 1996-03-28 | Combinação, e, formulação farmacêutica |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9506490.3A GB9506490D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
| GBGB9506489.5A GB9506489D0 (en) | 1995-03-30 | 1995-03-30 | Antiviral combinations |
| PCT/EP1996/001352 WO1996030025A1 (en) | 1995-03-30 | 1996-03-28 | Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI9607851B8 true BRPI9607851B8 (pt) | 2019-11-05 |
Family
ID=26306774
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9607851A BRPI9607851B8 (pt) | 1995-03-30 | 1996-03-28 | combinação e formulação farmacêutica. |
| BRPI9607851-0A BR9607851B1 (pt) | 1995-03-30 | 1996-03-28 | combinaÇço e formulaÇço farmacÊutica. |
| BRPI9612992-1A BRPI9612992B1 (pt) | 1995-03-30 | 1996-03-28 | Combinação, e, formulação farmacêutica |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9607851-0A BR9607851B1 (pt) | 1995-03-30 | 1996-03-28 | combinaÇço e formulaÇço farmacÊutica. |
| BRPI9612992-1A BRPI9612992B1 (pt) | 1995-03-30 | 1996-03-28 | Combinação, e, formulação farmacêutica |
Country Status (35)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000515852A (ja) * | 1996-06-25 | 2000-11-28 | グラクソ、グループ、リミテッド | Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ |
| US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| AU769660B2 (en) * | 1997-05-17 | 2004-01-29 | Glaxo Group Limited | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
| WO1998052570A1 (en) * | 1997-05-17 | 1998-11-26 | Glaxo Group Limited | Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
| GB9709945D0 (en) * | 1997-05-17 | 1997-07-09 | Glaxo Group Ltd | A novel salt |
| GB9809213D0 (en) * | 1998-04-29 | 1998-07-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| WO1999060988A2 (en) * | 1998-05-29 | 1999-12-02 | University Of Florida | Combination therapy for treatment of fiv infection |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
| US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| AP2220A (en) * | 2001-05-11 | 2011-03-24 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| TW200403061A (en) * | 2002-06-04 | 2004-03-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| KR20080032014A (ko) | 2003-01-14 | 2008-04-11 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
| KR20050119652A (ko) | 2003-03-24 | 2005-12-21 | 에프. 호프만-라 로슈 아게 | 역전사 효소 저해제로서의 벤질-피리다진온 |
| RU2006117793A (ru) | 2003-10-24 | 2007-12-10 | Иммунэйд Пти Лтд. (Au) | Способ лечения |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| CA2625047A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
| WO2008071587A2 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors |
| JP5467870B2 (ja) * | 2007-02-09 | 2014-04-09 | アルファファーム ピーティーワイ リミテッド | 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態 |
| WO2010135781A1 (en) | 2009-05-27 | 2010-12-02 | Immunaid Pty Ltd | Methods of treating diseases |
| PT3494972T (pt) | 2010-01-27 | 2024-02-12 | Viiv Healthcare Co | Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv |
| HK1220390A1 (zh) | 2013-08-29 | 2017-05-05 | Teva Pharmaceutical Industries Ltd. | 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂 |
| AU2015245217A1 (en) | 2014-04-08 | 2016-10-13 | Teva Pharmaceutical Industries Ltd. | Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir |
| CN117164657A (zh) | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
| CA2997106C (en) | 2015-09-08 | 2024-06-04 | Monash University | Lymph directing prodrugs |
| EP3675838A4 (en) | 2017-08-29 | 2021-04-21 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| CN115348864A (zh) | 2020-02-05 | 2022-11-15 | 纯技术Lyt股份有限公司 | 神经甾体的脂质前药 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| GB9104740D0 (en) | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
| ES2083668T5 (es) * | 1991-05-16 | 2001-06-16 | Glaxo Group Ltd | Combinaciones antiviricas que contienen analogos de nucleosido. |
| EP0639971B1 (en) * | 1992-05-13 | 1999-09-22 | The Wellcome Foundation Limited | Therapeutic combinations |
| US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| GB9417249D0 (en) | 1994-08-26 | 1994-10-19 | Wellcome Found | A novel salt |
| US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
| WO1997049410A1 (en) | 1996-06-25 | 1997-12-31 | Glaxo Group Limited | Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv |
| JP2000515852A (ja) | 1996-06-25 | 2000-11-28 | グラクソ、グループ、リミテッド | Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ |
| DE10226522A1 (de) | 2002-06-14 | 2003-12-24 | Degussa | Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung |
-
1996
- 1996-03-27 MY MYPI96001152A patent/MY115461A/en unknown
- 1996-03-28 SK SK1295-97A patent/SK283825B6/sk not_active IP Right Cessation
- 1996-03-28 KR KR1019970706824A patent/KR100542536B1/ko not_active Expired - Lifetime
- 1996-03-28 EA EA199700203A patent/EA000626B3/ru not_active IP Right Cessation
- 1996-03-28 MX MX9707316A patent/MX9707316A/es active IP Right Grant
- 1996-03-28 UA UA97094740A patent/UA60293C2/uk unknown
- 1996-03-28 CN CN96194050A patent/CN1103593C/zh not_active Expired - Lifetime
- 1996-03-28 AT AT96911953T patent/ATE220551T1/de active
- 1996-03-28 JP JP8528931A patent/JP2954357B2/ja not_active Expired - Lifetime
- 1996-03-28 RO RO97-01795A patent/RO117995B1/ro unknown
- 1996-03-28 DE DE200512000029 patent/DE122005000029I1/de active Pending
- 1996-03-28 GE GEAP19963898A patent/GEP20022647B/en unknown
- 1996-03-28 ES ES96911953T patent/ES2179193T3/es not_active Expired - Lifetime
- 1996-03-28 NZ NZ306419A patent/NZ306419A/xx not_active IP Right Cessation
- 1996-03-28 EE EE9700240A patent/EE04047B1/xx not_active IP Right Cessation
- 1996-03-28 SI SI9630494T patent/SI0817637T1/xx unknown
- 1996-03-28 CZ CZ19973090A patent/CZ295940B6/cs not_active IP Right Cessation
- 1996-03-28 HU HU9801571A patent/HU224010B1/hu active Protection Beyond IP Right Term
- 1996-03-28 DE DE1996622386 patent/DE122005000029I2/de active Active
- 1996-03-28 WO PCT/EP1996/001352 patent/WO1996030025A1/en active IP Right Grant
- 1996-03-28 CA CA002216634A patent/CA2216634C/en not_active Expired - Lifetime
- 1996-03-28 DK DK96911953T patent/DK0817637T3/da active
- 1996-03-28 US US08/930,225 patent/US6417191B1/en not_active Expired - Lifetime
- 1996-03-28 BR BRPI9607851A patent/BRPI9607851B8/pt unknown
- 1996-03-28 PT PT96911953T patent/PT817637E/pt unknown
- 1996-03-28 PL PL96322532A patent/PL187085B1/pl unknown
- 1996-03-28 AP APAP/P/1997/001089A patent/AP652A/en active
- 1996-03-28 BR BRPI9607851-0A patent/BR9607851B1/pt active IP Right Grant
- 1996-03-28 DE DE69622386T patent/DE69622386T2/de not_active Expired - Lifetime
- 1996-03-28 TR TR97/01074T patent/TR199701074T1/xx unknown
- 1996-03-28 BR BRPI9612992-1A patent/BRPI9612992B1/pt not_active IP Right Cessation
- 1996-03-28 EP EP96911953A patent/EP0817637B1/en not_active Expired - Lifetime
- 1996-03-28 AU AU54972/96A patent/AU715213B2/en not_active Expired
- 1996-03-29 IL IL11772796A patent/IL117727A/xx not_active IP Right Cessation
-
1997
- 1997-09-17 OA OA70075A patent/OA10616A/en unknown
- 1997-09-29 NO NO19974510A patent/NO313787B1/no not_active IP Right Cessation
-
2005
- 2005-05-04 LU LU91171C patent/LU91171I2/fr unknown
- 2005-05-09 FR FR05C0022C patent/FR05C0022I2/fr active Active
- 2005-05-09 NL NL300195C patent/NL300195I2/nl unknown
- 2005-05-24 NO NO2005014C patent/NO2005014I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9607851B8 (pt) | combinação e formulação farmacêutica. | |
| BRPI0406760A (pt) | Composições e métodos para terapia antiviral de combinação | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| CZ283765B6 (cs) | 1,3-Oxathiolannukleosidové analogy | |
| KR920021148A (ko) | 항바이러스 조성물 | |
| BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
| BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
| RU94013464A (ru) | Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции | |
| AR082068A2 (es) | Analogos de nucleosidos fluorados modificados | |
| BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
| BR9909474A (pt) | Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol | |
| BR9710585A (pt) | Composição para administração enteral, processo para melhorar a resistência fìsica ou desempenho atlético de um mamìfero, para aumentar a concentração de proteìna, massa corporal sem gordura ou massa muscular em um mamìfero, para diminuir a deposição de gordura corporal para uma dada ingestão calórica e aumentar a perda de gordura corporal em um mamìfero, para tratar os efeitos catabólicos de doença em um mamìfero, para aperfeiçoar a resistência fìsica ou o desempenho atléticode um mamìfero, e, para aumentar a massa de um corpo de carne magra de um mamìfero e diminuir a deposição de gordura | |
| BR0116251A (pt) | composição de lágrimas artificiais contendo uma combinação de três demulcentes | |
| BR9808060A (pt) | Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica. | |
| NO986034L (no) | Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| BR9913791A (pt) | Combinação, formulação farmacêutica, método para o tratamento de um mamìfero, incluindo um humano, com uma infecção por hbv, uso de uma combinação, e, embalagem para pacientes | |
| BR9916919A (pt) | Compósito de sulfonamida e seu uso | |
| BRPI0407271A (pt) | Composição anti-helmìntica | |
| Amadori et al. | Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma | |
| DE60207824D1 (de) | Cytidin-diphosphocholin gegen diabetische neuropathie | |
| AR026255A1 (es) | Combinaciones antivirales. | |
| EA199801046A1 (ru) | Комбинации, содержащие vx478, зидовудин и/или 1592u89, для применения при лечении вич |